U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H48N4O8
Molecular Weight 616.7455
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALVESPIMYCIN

SMILES

CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O

InChI

InChIKey=KUFRQPKVAWMTJO-LMZWQJSESA-N
InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1

HIDE SMILES / InChI

Description

Alvespimycin (17-desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin) (17-DMAG; NSC 707545) is an inhibitor of the molecular chaperone heat shock protein HSP90. Alvespimycin is a derivative of antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Alvespimycin was studied in clinical trials for the treatment of solid tumors and hematologic malignancies however its development was discontinued.

CNS Activity

CNS Active
3913
Curator's Comment: Alvespimycin (17-DMAG) is brain penetrant and CNS active in animals. No human data available.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 62.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase I
428
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
DLT: Acidosis, Nausea...
Other AEs: Blood creatinine increased...
Dose limiting toxicities:
Acidosis (grade 3, 25%)
Nausea (grade 2, 25%)
Hyponatremia (grade 3, 25%)
Diarrhea (grade 3, 25%)
Anorexia (grade 2, 25%)
Dehydration (grade 3, 25%)
Vomiting (grade 2, 25%)
AST increased (grade 4, 25%)
Acute hypotension (grade 4, 25%)
Fatigue (grade 3, 25%)
Fever (grade 2, 25%)
Hypoalbuminemia (grade 3, 25%)
Acute renal failure (grade 5, 25%)
Other AEs:
Blood creatinine increased (grade 3, 25%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
24 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 24 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 24 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.702
unhealthy, ADULT
n = 11
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.702
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.702
80 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 80 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 80 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.6
unhealthy, ADULT
n = 8
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.6
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.6
32 mg/m2 2 times / week multiple, intravenous
Studied dose
Dose: 32 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 32 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
DLT: Acute myocardial infarction, Cardiac ischemia...
Dose limiting toxicities:
Acute myocardial infarction (grade 5, 50%)
Cardiac ischemia (grade 3-4, 50%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
AEs

AEs

AESignificanceDosePopulation
Anorexia grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Fever grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Nausea grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Vomiting grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Blood creatinine increased grade 3, 25%
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Fatigue grade 3, 25%
DLT
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Hypoalbuminemia grade 3, 25%
DLT
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Acidosis grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Dehydration grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Diarrhea grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Hyponatremia grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
AST increased grade 4, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Acute hypotension grade 4, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Acute renal failure grade 5, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Page: p.5, 6
Diarrhea grade 3-4, 9%
DLT
24 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 24 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 24 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.702
unhealthy, ADULT
n = 11
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.702
Cardiac ischemia grade 3-4, 50%
DLT
32 mg/m2 2 times / week multiple, intravenous
Studied dose
Dose: 32 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 32 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
Acute myocardial infarction grade 5, 50%
DLT, Disc. AE
32 mg/m2 2 times / week multiple, intravenous
Studied dose
Dose: 32 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 32 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Page: p.701, 702
Sourcing

Sourcing

Vendor/AggregatorIDURL
AK Scientific, Inc. (AKSCI)
X8446
http://www.aksci.com/item_detail.php?cat=X8446
Achemtek
0101-002334
http://www.achemtek.com/467214-20-6
Acorn PharmaTech
ACN-046374
http://www.acornpharmatech.com/
Active Biopharma
ABP000223
http://www.activebiopharma.com/150270-08-9
Active Biopharma
ABP000584
http://www.activebiopharma.com/467214-21-7
Aurora Fine Chemicals LLC
A13.105.467
http://online.aurorafinechemicals.com/info?ID=A13.105.467
Aurum Pharmatech LLC
W-5374
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5374
AvaChem Scientific
6006
https://www.avachem.com/productSearch.asp?6006
BOC Sciences
150270-08-9
https://www.bocsci.com/17-dimethylaminoethylamino-17-demethoxygeldanamycin-cas-150270-08-9-item-122708.html
BioCrick
BCC1346
http://www.biocrick.com/Alvespimycin-BCC1346.html
Chem Scene
CS-0912
http://www.chemscene.com/467214-20-6.html
ChemMol
99046992
http://www.chemmol.com/chemmol/99046992.html
ChemShuttle
159942
http://www.chemshuttle.com/catalogsearch/result/?q=467214-20-6&cat=
Chemspace
CSSB00116207116
https://chem-space.com/CSSB00116207116
DC Chemicals
DC36820
http://www.dcchemicals.com//product_show-Alvespimycin.html
Excenen
EX-A1103
http://www.excenen.com/searchresultlist.php?id=467214-20-6
Hairui
HR116175
http://www.hairuichem.com/en/product/467214-20-6.html
Matrix Scientific
89480
https://www.matrixscientific.com/089480.html
MedChem Express
HY-10389
https://www.medchemexpress.com/alvespimycin.html
MolPort
MolPort-006-666-027
https://www.molport.com/shop/molecule-link/MolPort-006-666-027
MuseChem
I003618
https://www.musechem.com/product/I003618.html
MuseChem
M097169
https://www.musechem.com/product/M097169.html
OChem
26905
http://www.ocheminc.com/index.php?act=psearch&pid=214D206
Oakwood
M03709
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=128507&ExtHyperLink=1
Smolecule
S518217
http://www.smolecule.com/products/s518217
THE BioTek
bt-258596
https://www.thebiotek.com/product/inhibitors/bt-258596
abcr GmbH
AB200576
http://www.abcr.com/shop/en/AB200576
eNovation Chemicals
D567341
https://www.enovationchem.com/ProductDetails.asp?ProductID=D567341
eNovation Chemicals
Y1012794
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1012794
PubMed

PubMed

TitleDatePubMed
Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90.
2003 Apr
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
2006 Nov 1
The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
2006 Oct
Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis.
2009 Apr 15
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
2009 Jul
Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.
2010 Jan 20
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
2011 Jul
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
2012 Sep 1
Patents

Patents

20050026894
3

Sample Use Guides

In Vivo Use Guide
Phase 1 study. Patients with advanced acute myeloid leukemia (AML) received escalating doses of intravenous alvespimycin (8-32 mg/m(2)), twice weekly, for 2 of 3 weeks. Alvespimycin was well tolerated; the maximum-tolerated dose was 24 mg/m(2) twice weekly. Common toxicities included neutropenic fever, fatigue, nausea and diarrhea. Cardiac DLTs occurred at 32 mg/m(2) (elevated troponin and myocardial infarction). Pharmacokinetics revealed linear increases in C(max) and area under the curve (AUC) from 8 to 32 mg/m(2) and minor accumulation upon repeated doses. Recommended phase 2 dose is 24 mg/m(2).
Route of Administration: Intravenous
In Vitro Use Guide
One hepatic cell line (L02) and two HCC cell lines (Huh7 and HepG2) were heated at 42 °C for 0, 0.5 or 4 h with or without 100 nM alvespimycin (17-DMAG).
Name Type Language
ALVESPIMYCIN
INN   WHO-DD  
INN  
Official Name English
Alvespimycin [WHO-DD]
Common Name English
alvespimycin [INN]
Common Name English
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-((2-(DIMETHYLAMINO)ETHYL)AMINO)-13-HYDROXY-8,14-DIMETHOXY-4,10,12,16-TETRAMETHYL-3,20,22-TRIOXO-2-AZABICYCLO(16.3.1)DOCOSA-1(21),4,6,10,18-PENTAEN-9-YL CARBAMATE
Common Name English
GELDANAMYCIN, 17-DEMETHOXY-17-((2-(DIMETHYLAMINO)ETHYL)AMINO)-
Common Name English
NSC-707545
Code English
DMAG
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2516
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C38142
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
INN
8811
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
PUBCHEM
5288674
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
FDA UNII
001L2FE0M3
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
NSC
707545
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID00963646
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
MESH
C448659
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
CHEBI
65324
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
WIKIPEDIA
17-Dimethylaminoethylamino-17-demethoxygeldanamycin
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
SMS_ID
100000127463
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
DRUG BANK
DB12442
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
CAS
467214-20-6
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL383824
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
EVMPD
SUB33529
Created by admin on Fri Dec 15 16:25:37 GMT 2023 , Edited by admin on Fri Dec 15 16:25:37 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of ALVESPIMYCIN
SALT/SOLVATE (PARENT)
Structure of ALVESPIMYCIN HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966